Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-AN-A04A-01A-21R-A034-07

— · C

929c9c11-9a01-57a0-b4d3-9a94ad48b141

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C
overall_survival_months
3

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.630
  • ANGIOGENESIS+0.550
  • PANCREAS_BETA_CELLS+0.480
  • MYC_TARGETS_V1+0.450
  • HEDGEHOG_SIGNALING+0.440
  • COAGULATION+0.390
  • APICAL_JUNCTION+0.380
  • MYOGENESIS+0.350
  • UV_RESPONSE_DN+0.340
  • ESTROGEN_RESPONSE_EARLY+0.330

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.250
  • IL6_JAK_STAT3_SIGNALING-0.240
  • BILE_ACID_METABOLISM-0.230
  • ADIPOGENESIS-0.190
  • INTERFERON_GAMMA_RESPONSE-0.190
  • CHOLESTEROL_HOMEOSTASIS-0.160
  • PEROXISOME-0.150
  • E2F_TARGETS-0.130
  • ALLOGRAFT_REJECTION-0.110
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.110

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-77-8130-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.831
2TCGA-60-2708-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.813
3MBCProject_6109_T1A_RNA
breast-umap@18
—C0.773
4SRR8943050
bladder-landscape@3
——0.759
5C3L-01838
lung-landscapes@6
—cohortSQ10.758
6TCGA-UY-A8OC-01A-11R-A36F-07
bladder-landscape@3
——0.753
7SRR5903555
lung-landscapes@6
—cohortSQ10.747
8TCGA-34-5928-01A-11R-1820-07
lung-landscapes@6
—cohortSQ10.745
920020076.Her2HRpos
breast-umap@18
—C0.725
10MBCProject_1181_T1_RNA
breast-umap@18
—B0.721

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 35 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.630Inavolisib— uncovered
ANGIOGENESIS0.550Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.480Cobimetinib— uncovered
MYC_TARGETS_V10.450Inavolisib— uncovered
HEDGEHOG_SIGNALING0.440Inavolisib— uncovered
COAGULATION0.390Binimetinib— uncovered
APICAL_JUNCTION0.380Inavolisib— uncovered
MYOGENESIS0.350Inavolisib— uncovered
UV_RESPONSE_DN0.340Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.330Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.330Idelalisib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
KRAS_SIGNALING_UP0.270Inavolisib— uncovered
MYC_TARGETS_V20.260Idelalisib— uncovered
HYPOXIA0.250Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.250Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.200Inavolisib— uncovered
P53_PATHWAY0.190Idelalisib— uncovered
KRAS_SIGNALING_DN0.180Remibrutinib— uncovered
IL2_STAT5_SIGNALING0.170Idelalisib— uncovered